Fig. 3From: Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in USTornado diagram for one-way sensitivity analyses of nusinersen versus BSC. QALY quality-adjusted life year. The values in the parenthesis in the y-axes represents the lower and upper input, respectively. *Lower input corresponds to higher incremental cost-effectiveness ratio and vice versaBack to article page